Arrowhead Pharmaceuticals’ (ARWR) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a report released on Thursday, Benzinga reports.

ARWR has been the subject of several other research reports. Morgan Stanley decreased their target price on Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an equal weight rating for the company in a research report on Monday, May 13th. The Goldman Sachs Group initiated coverage on Arrowhead Pharmaceuticals in a report on Wednesday, June 5th. They issued a neutral rating and a $31.00 price target on the stock. Chardan Capital reissued a buy rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, June 3rd. Finally, HC Wainwright reissued a buy rating and issued a $90.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, June 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals has an average rating of Moderate Buy and a consensus target price of $47.89.

Arrowhead Pharmaceuticals Trading Up 0.9 %

Shares of ARWR opened at $23.79 on Thursday. The firm has a market cap of $2.95 billion, a price-to-earnings ratio of -5.60 and a beta of 0.94. The stock has a 50 day moving average of $24.07 and a 200-day moving average of $28.25. Arrowhead Pharmaceuticals has a 52 week low of $20.67 and a 52 week high of $39.83.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, May 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative return on equity of 140.72% and a negative net margin of 163.32%. The company’s revenue for the quarter was down 100.0% on a year-over-year basis. During the same period last year, the business posted $0.45 earnings per share. On average, sell-side analysts predict that Arrowhead Pharmaceuticals will post -3.05 earnings per share for the current fiscal year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Victoria Vakiener sold 1,799 shares of Arrowhead Pharmaceuticals stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $23.31, for a total transaction of $41,934.69. Following the sale, the director now owns 30,205 shares of the company’s stock, valued at approximately $704,078.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.50% of the stock is owned by company insiders.

Institutional Trading of Arrowhead Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Washington Trust Advisors Inc. bought a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter worth $25,000. Neo Ivy Capital Management bought a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter worth $41,000. Quest Partners LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter worth $45,000. Friedenthal Financial bought a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter worth $51,000. Finally, Headlands Technologies LLC raised its stake in shares of Arrowhead Pharmaceuticals by 7,696.8% in the 1st quarter. Headlands Technologies LLC now owns 2,417 shares of the biotechnology company’s stock worth $69,000 after buying an additional 2,386 shares in the last quarter. Institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.